Medtronic (NYSE:MDT) EVP Sells $5,132,120.04 in Stock

Medtronic PLC (NYSE:MDT) EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president directly owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Medtronic Price Performance

MDT traded up $0.32 during trading on Thursday, reaching $96.97. The company’s stock had a trading volume of 7,910,637 shares, compared to its average volume of 8,597,516. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The firm has a fifty day simple moving average of $98.98 and a two-hundred day simple moving average of $96.83. The company has a market cap of $124.32 billion, a price-to-earnings ratio of 27.01, a PEG ratio of 2.43 and a beta of 0.71. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.88% and a net margin of 13.00%.The company had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. During the same quarter in the previous year, the company posted $1.38 earnings per share. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, analysts anticipate that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 2.9%. The ex-dividend date was Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is presently 79.11%.

Institutional Trading of Medtronic

A number of large investors have recently modified their holdings of the stock. Curbstone Financial Management Corp lifted its stake in Medtronic by 1.8% during the fourth quarter. Curbstone Financial Management Corp now owns 5,594 shares of the medical technology company’s stock worth $537,000 after purchasing an additional 100 shares during the last quarter. New England Capital Financial Advisors LLC increased its stake in Medtronic by 7.8% in the fourth quarter. New England Capital Financial Advisors LLC now owns 1,403 shares of the medical technology company’s stock valued at $135,000 after purchasing an additional 101 shares during the last quarter. Ipsen Advisor Group LLC raised its holdings in Medtronic by 1.7% during the fourth quarter. Ipsen Advisor Group LLC now owns 5,952 shares of the medical technology company’s stock worth $572,000 after purchasing an additional 101 shares in the last quarter. Quadrant Capital Group LLC lifted its position in shares of Medtronic by 0.3% during the 4th quarter. Quadrant Capital Group LLC now owns 32,477 shares of the medical technology company’s stock worth $3,120,000 after buying an additional 101 shares during the last quarter. Finally, Baker Tilly Wealth Management LLC boosted its holdings in shares of Medtronic by 3.3% in the 4th quarter. Baker Tilly Wealth Management LLC now owns 3,221 shares of the medical technology company’s stock valued at $309,000 after buying an additional 102 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analyst Ratings Changes

MDT has been the subject of several analyst reports. Leerink Partners dropped their price target on shares of Medtronic from $120.00 to $119.00 and set an “outperform” rating for the company in a research note on Wednesday, February 18th. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. Morgan Stanley raised their price objective on Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 19th. Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a research report on Monday, January 5th. Finally, Wells Fargo & Company assumed coverage on shares of Medtronic in a research note on Friday, January 30th. They issued an “overweight” rating and a $114.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and an average price target of $110.84.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).